The Synergy Matrix Covers The Entire MASLD Management Chain
We are the only POCT manufacturer that can provide complete coverage from fat quantification to fibrosis assessment.
Screening Phase
FattaLab®
MAP-based liver fat quantification for accessible screening and repeated follow-up in metabolic health workflows.
Diagnosis / Staging Phase
Liverscan®
LSM-based liver stiffness assessment for fibrosis-related evaluation and clinical liver assessment workflows.
Treatment Monitoring Phase
Liverscan® + FattaLab®
LSM and MAP together support longitudinal monitoring across liver fat and stiffness-related workflows.
Product Comparison
Compare Product Fit by Workflow
Decision Point
FattaLab®
Liverscan®
Assessment Need
Rapid, AI-driven liver fat quantification (MAP) for screening and longitudinal therapy monitoring
Dual-parameter liver assessment: real-time B-mode guided stiffness measurement (LSM) for fibrosis staging + AI-powered fat quantification (MAP) for steatosis grading — one probe, one exam, two answers
Recommended Setting
GLP-1 and weight management clinics, retail pharmacies, corporate wellness, insurance health checks, large-scale preventive screening
Hospitals, specialty clinics, health management centers, Medical imaging center, Community-based chronic disease outreach
Workflow Role
First-line metabolic liver risk screening and GLP-1 therapy companion — baseline, monitoring, and treatment response tracking
Point-of-care fibrosis staging and steatosis grading across the full liver disease spectrum—chronic HBV/HCV surveillance, MASLD/MASH management, pre-procedural risk stratification, and population-level screening
Product Resources
Compare, Validate, and Download
Product Comparison
Compare FattaLab® and Liverscan® by assessment need, workflow, clinical setting, and buyer use case.